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Microinjection of Superior Cervical Ganglion Neurons
for Studying Axon Degeneration
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Abstract
Primary cultures of neurons of the peripheral nervous system have been successfully used for studying many
aspects of neuronal development and survival, including investigations into the mechanisms of axon
degeneration. In this chapter, we describe how to prepare and microinject dissociated cultures of sympa-
thetic neurons of the superior cervical ganglion (SCG) specifically for use in highly controlled and targeted
assays of axon survival and degeneration.
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1 Introduction
Primary cultures of early postnatal sympathetic neurons of the
superior cervical ganglion (SCG), which are dependent on nerve
growth factor (NGF) for survival, are an established model system
for studying many aspects of neuronal biology. SCG neurons pre-
dominantly extend axon-like neurites [1], and these can grow
several millimeters in just a few days making them ideally suited to
investigations of axonal function. Indeed, studies in SCG cultures,
together with studies in primary cultures of mid-to-late embryonic
stage sensory neurons of the dorsal root ganglion (DRG), have
contributed significantly to our understanding of the key molecular
regulators of axon degeneration caused by physical injury (Waller-
ian degeneration) or related degeneration triggered by chemical
insults [2, 3]. Crucially, similar mechanisms appear to be involved
during the degeneration of axons in a number of neurodegenera-
tive disorders [2].
Targeted suppression of gene expression by RNA interference
and exogenous expression of wild-type or modified proteins are
useful tools for probing the roles of specific genes in cellular pro-
cesses. SCG and DRG neuron cultures are relatively resistant to
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standard chemical transfection, so viral transduction of constructs
has become a favored method for achieving these outcomes, espe-
cially in DRG explant or spot cultures (see Chapters 4 and 5).
However, microinjection has also proved successful for delivery of
expression vectors and other materials into cultured neurons and,
in particular, SCG neurons, where larger cell bodies/nuclei and a
greater ability to tolerate injection stresses make the process much
more efficient than for DRG neurons or other neuron types
(althoughDRG neurons can be injected, if desired). Microinjection
is a technically challenging and low-throughput method targeting
relatively small numbers of cells. While this makes it unsuited to
biochemical analyses, it does provide a unique degree of precision
that is particularly useful in studies of neurite (axon) degeneration
in primary neuron cultures. For example, it provides a greater
degree of control over the concentrations of the materials being
introduced, as well as greater flexibility over the type and combina-
tions of material that can be used. The ability to target small
numbers of neurons in specific locations can also provide better
spatial resolution of individual neurites than nontargeted methods.
In addition, after an initial financial outlay on some specialized
equipment, subsequent costs are relatively low and the ability to
use standard mammalian expression vectors in injections, with no
theoretical size restriction, is a particular advantage.
In this chapter, we present core methods for preparing and
microinjecting primary cultures of dissociated mouse SCG neurons
with the specific aim of studying neurite degeneration. A procedure
for the dissociation of mouse SCG neurons, which is adapted from
an earlier protocol for the dissociation of rat SCG neurons [4], is
described first. Dissociated cultures are required, so that individual
neurons can be targeted easily. Rat SCG neurons can be used if
preferred, but most studies of neurite degeneration are performed
in mouse cultures due to the growing number of useful mutant
mouse models with altered axon survival [2, 3]. Our method also
describes a minor modification for the preparation of independent
cultures from individual mice, for example, if litters of mixed geno-
types are being processed. We next describe the basic procedure for
microinjection of SCG neurons for the specific purpose of tracking
the survival of their neurites. Crucially, in addition to any test
materials being injected, a means for fluorescent labeling must be
included in order that the injected neurons and their neurites can
be visualized separately from the mass culture (Fig. 1). While we do
not provide specific details, injected test materials have, in the past,
includedmammalian expression vectors and small interfering RNAs
(siRNAs) [5–11], although purified proteins and other compounds
can also be injected. We additionally describe a simple method for
transecting the labeled neurites with a scalpel blade to trigger
Wallerian degeneration, if required (Fig. 1).
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Finally, although this chapter is limited to a description of
microinjection as a tool for assessing the survival of individual
neurites (intact or transected) in response to various injected mate-
rials, it is important to note that there are many other potential
applications of the technique. For example, microinjection of SCG
neurons has already proven useful for live-imaging studies of axonal
transport [7, 11, 12] and could easily be applied to other aspects of
axon biology, such as regeneration.
Fig. 1 Representative images of a generic microinjection experiment showing degeneration of labeled neurites
after transection. (a) Low-magnification fluorescence and phase-contrast images of a region of a dissociated
culture of wild-type SCG neurons 48 h after injection of a small cluster of the neurons with a fluorescent
protein expression vector (pDsRed2). The series of images shows the same area before, immediately after
(0 h), and 8 h after the introduction of a cut with a scalpel blade. Labeled cell bodies of the injected neurons
are seen to the left of the fluorescence images with some of their labeled neurites extending to the right, the
distal ends of which become disconnected from their cell bodies following transection and degenerate within
8 h. Phase-contrast images reveal that changes in the relatively few labeled neurites are occurring within a
dense network of unlabeled SCG neurons and neurites that appear grossly unaffected except for a small
amount of retraction and neurite regeneration occurring at the cut site. (b) Higher magnification fluorescence
images of the boxed regions in (a) for better visualization of the complete loss of continuity of the labeled,
transected neurites by 8 h after cut. Scale bars ¼ 100 μm
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2 Materials
2.1 Dissociation
and Culture of SCG
Neurons
Solution preparation and coating of dishes should be performed in
a laminar flow cabinet or Class II biological safety cabinet. Sterile,
ultrapure water (deionized, filtered water purified to 18.2 MΩ·cm
resistivity at 25 C) should be used for solutions, as applicable.
1. Trypsin solution: Dissolve lyophilized trypsin from bovine pan-
creas in PBS() (phosphate-buffered saline withoutcalcium
chloride and magnesium chloride) at a concentration of
0.025%. Alternatively, the 0.025% working solution can be
diluted from a 0.25% concentrated stock solution. Store ali-
quots at 20 C.
2. Collagenase solution: Dissolve desiccated type 2 collagenase
(storage at 4 C) in PBS (withcalcium chloride and magnesium
chloride) at a concentration of 0.2%, and filter sterilize through
a 0.22 μm filter. Large batches can be prepared and aliquots
stored at 20 C; however, best results are obtained with
freshly prepared solution. Activity of the desiccated collagenase
may vary between batches, so incubation times should be
adjusted accordingly.
3. SCGmedium: DMEM (with 4500mg/l glucose and 110mg/l
sodium pyruvate) supplemented with 10% fetal bovine serum
(FBS) (see Note 1), 1 penicillin/streptomycin, 2 mM L-glu-
tamine, 2–4 μg/ml aphidicolin (seeNote 2), and 25–50 ng/ml
2.5S NGF or 100 ng/ml 7S NGF (see Note 3). Concentrated
stock solutions of each supplement are as follows: 100 peni-
cillin/streptomycin (10,000 U/ml penicillin and 10,000 μg/
ml streptomycin in 10 mM citrate buffer), 100 L-glutamine
(200 mM), 4 mg/ml aphidicolin in DMSO, and 100 μg/ml
2.5S or 7S NGF prepared as per supplier instructions. Aliquots
of each supplement are stored at 20 C. SCG medium with-
out aphidicolin and NGF can be stored for several weeks at
4 C with the two omitted items being added fresh as needed.
4. Low-sided (uncoated) 35 mm μ-Dishes (ibidi) coated with
poly-L-lysine and laminin (see Note 4): First, cover just the
uncoated coverslip insert bases of the dishes with 1 ml of a
solution of 20 μg/ml poly-L-lysine hydrobromide
(Mw 300,000) dissolved in water. The working poly-L-lysine
solution can be diluted from aliquots of a 2.5 mg/ml stock
solution in water (store at 20 C). After at least 1 h at room
temperature, remove the poly-L-lysine solution and wash the
coverslip insert base once with sterile, ultrapure water before
leaving to air dry completely. Dried poly-L-lysine-coated dishes
can be stored for several weeks at 4 C wrapped in parafilm. For
subsequent laminin coating, 1 mg/ml laminin (stored as 20 μl
aliquots in 1.5 ml microfuge tubes at 20 C) is diluted to
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20 μg/ml in DMEM (980 μl per 20 μl aliquot) and ~50–100 μl
of the solution used to coat a small circular area, typically
7–10 mm in diameter, in the center of each coverslip insert
base. It is important not to use SCG medium to dilute the
laminin as the presence of FBS will interfere with coating. After
1–2 h at room temperature, the laminin solution is aspirated
immediately prior to addition of the dissociated neurons. The
laminin-coated area should not be allowed to dry.
2.2 Microinjection 1. A complete microinjection system setup for injecting on an
inverted microscope with a 32/40 objective and optional
4/5 objective and a holder for a 35 mm dish (see Note 5).
The microscope should sit on an anti-vibration table. The
procedures for injection described in this chapter are based on
an Eppendorf system (Fig. 2). In it, an Eppendorf FemtoJet®
microinjector pressurizes an injection capillary that is attached
to a high resolution x,y,z motor module and an Eppendorf
TransferMan® micromanipulator. The micromanipulator
allows proportional control over capillary movements. The
Fig. 2 Components of a typical microinjection system for injecting SCG neurons in dissociated cultures. The
system shown does not include a CO2 supply
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motor module can be attached to the microscope via a
manufacturer-specific attachment or can be positioned using a
universal stand. Ideally, the microscope should have a heated
stage. An environment chamber with regulated CO2 supply is
optional.
2. FemtoTip® injection capillaries (Eppendorf) with screw-in
thread for quick assembly into the capillary holder of the Fem-
toJet® microinjector (see Note 6).
3. 0.22 μm centrifuge tube filter columns such as Corning®
Costar® Spin-X® centrifuge tube filters.
4. Eppendorf Microloader™ pipette tips for loading injection mix
into injection capillaries and for removing any excess.
5. Sterile disposable blades for attachment to a nondisposable
scalpel handle or sterile disposable surgical scalpels with a poly-
styrene handle. Blades should be curved with a relatively long
cutting edge (e.g. No. 10 or No. 22).
3 Methods
All steps are performed at room temperature in a horizontal laminar
flow cabinet, unless indicated otherwise.
3.1 Dissociation
and Culture of SCG
Neurons
1. Dissect superior cervical ganglia from mousepups at any age up
to 2–3 days after birth as described in Chapter 2. Typically, 1–2
ganglia will provide sufficient dissociated neurons for a single
dish with a laminin-coated area of 7–10 mm in diameter. Nerve
fibers, capillaries, or other encapsulating tissue should be
cleaned from the ganglia before proceeding.
2. Transfer ganglia to 0.025% trypsin solution, prewarmed to
37 C, using a pair of sterile No. 5 forceps (sterilized in 70%
ethanol and air dried before use). Use 5 ml of trypsin solution
in a 15-ml tube for ganglia from multiple mice of the same
genotype (up to 20–30) or, if processing individual mice sepa-
rately, use 1 ml of trypsin solution in separate 1.5 ml tubes for
each pair of ganglia. Incubate at 37 C in a waterbath for no
more than 20–30 min.
3. Transfer the ganglia to 0.2% collagenase solution, prewarmed
to 37 C, using a sterile 1 ml tip attached to an appropriate
pipetman/pipettor. Transfer in as small a volume of trypsin
solution as possible. As in step 2, use 5 ml of collagenase
solution in a 15-ml tube for multiple ganglia or 1 ml of colla-
genase solution in separate 1.5 ml tubes for individual pairs of
ganglia. Incubate at 37 C in a waterbath for no more than
20–30 min.
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4. Transfer the ganglia to a fresh 15 ml tube or separate 1.5 ml
tubes, as appropriate, using a sterile 1 ml tip attached to an
appropriate pipetman/pipettor. Transfer in as small a volume
of the collagenase solution as possible (ideally <50 μl). Add
0.5 ml of SCG medium and triturate the ganglia using a 1-ml
tip attached to an appropriate pipetman/pipettor by drawing
the ganglia into the tip while it is pressed firmly to the base of
the tube and then expel back into the tube normally. Repeat no
more than ten times before transferring the cell suspension to a
standard, uncoated 35-mm tissue culture dish. If any ganglia
remain intact, transfer them back into the tube in as small a
volume of media as possible, and repeat the trituration step
using another 0.5 ml of SCG medium and add this to the
previous cell suspension in the dish. Remove and discard any
undissociated tissue remaining after the second trituration (see
Note 7).
5. Preplating: Add additional SCGmedium to the cell suspension
in the standard, uncoated tissue culture dish to give a final
volume of 1.5 ml, and incubate for 1–2 h in a 5% CO2 incuba-
tor at 37 C. Non-neuronal cells, appearing phase-dark on an
inverted phase-contrast microscope, will adhere to the dish
while the phase-bright neurons will remain in suspension.
This step is not essential (see Note 8).
6. Transfer the cell suspension from steps 4 or 5 to a fresh 15-ml
tube or separate 1.5 ml tubes, as required, using a 1-ml tip
attached to an appropriate pipetman/pipettor. Tap the dish
several times if preplating was performed to maximize collec-
tion of neurons. Pellet cells at 200  g in a bench-top centri-
fuge for 5 min.
7. Remove the majority of the supernatant leaving a small volume
of medium (<20–30 μl) at the bottom of the tube, so as not to
disturb the cell pellet. Add sufficient fresh SCG medium for
plating; 35–40 μl is sufficient for one dish with a laminin-
coated area 7–10 mm in diameter (see Note 9). Resuspend
the cell pellet using a 1-ml tip attached to an appropriate pipet-
man/pipettor by drawing the cell suspension into the tip while
it is pressed to the base of the tube. Repeat five times with
significantly less pressure than used during initial trituration
(step 4).
8. Transfer 35–40 μl of neuronsuspension (or other appropriate
volume as determined by cell counting, if performed) to the
laminin-coated area of each poly-L-lysine/laminin-coated dish.
The laminin solution should have been removed just prior to
addition of the cell suspension. Avoid repeated pipetting that
creates electrostatic forces that cause neurons to cluster in the
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center of the laminin-coated area. Incubate for 2 h in a 5% CO2
incubator at 37 C.
9. Check neurons have attached to the dish on an inverted phase-
contrast microscope. Short neurites extending from the
attached neurons should already be visible. Flood each dish
with at least 1 ml of SCG medium prewarmed to 37 C.
10. Replace the SCG medium 1 day after initial plating and then
every 2–3 days thereafter. Neurons can be microinjected at any
time from 3 days in vitro (DIV) onwards, although assays for
injury-induced axon degeneration are best performed after
5 DIV when neurites are more developed.
3.2 Microinjection
of SCG Neurons
and Neurite
Degeneration Assays
1. Turn on the microinjector, micromanipulator, and microscope
heated stage (set to 37 C, if present). The microinjector will
take a few minutes to pressurize. If an environment chamber
with CO2 supply is also present, set for a 5% CO2 level and add
some sterile, ultrapure water to a tray in the chamber to main-
tain humidity.
2. Prepare injection mix(es): These should be freshly prepared on
the day of injection. For each mix, dilute water-dissolved test
components (expression vectors, siRNAs, etc.) to 2 the
desired final concentration in sterile, ultrapure water and com-
bine with an equal volume of 1 PBS() (withoutcalcium
chloride and magnesium chloride). The final injection mix
will thus have PBS() at 0.5 and each test component at
the desired concentration. A 20-μl mixture, combining 10 μl
of water-based components with 10 μl of 1 PBS(), is usually
sufficient for one injection session. An expression vector for a
fluorescent protein or a fluorescently conjugated dextran
(molecular weight of 10,000 or less) should be co-injected
with the other components being tested, so that the injected
neurons and their neurites can be visualized (see Note 10).
Stock solutions of conjugated dextrans are usually dissolved
in 1 PBS() and should thus be added as part of the 1
PBS() half of the injection mix. The total nucleic acid con-
centration in an injection mix should not exceed 200 ng/μl.
3. Spin the injection mix through a 0.22-μm centrifuge tube filter
column in a microfuge at 14,000  g for 5 min to remove any
particulate material that could block the injection capillary.
4. Load the injection mix into an injection capillary: Aspirate
2–3 μl of injection mix into a microloader pipette tip using an
appropriate pipetman/pipettor and expel directly into the tip
end of the injection capillary while holding it vertically in its tip
protector. Remove any air bubbles that might impede flow with
gentle flicking or by aspirating with the microloader. Remove
the tip protector and screw the loaded injection capillary into
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the FemtoJet® capillary holder, and attach the holder to the x,y,
z motor module. Do not apply air pressure to the capillary until
step 6.
5. Place a dish of dissociated SCG neurons into the dish holder on
the microscope stage. Angle the injection capillary at 30–50
from the horizontal, as preferred, and with the micromanipula-
tor joystick set to coarse movements, position the tip of the
injection capillary at the surface of the medium in the center of
the microscope field of view. A combination of viewing from
above and through the microscope using the lowmagnification
objective (if present) will facilitate initial positioning. Once
centered, set the micromanipulator joystick to fine movements,
and viewing through the 32/40 objective, lower the capil-
lary tip into the medium until it is positioned just above the
SCG neurons on the base of the dish. The tip should be able to
touch the surface of the SCG neurons within one-quarter turn
of the joystick (which controls movement in the z plane).
6. Microinject neurons in the dish: Set the compensation pressure
(Pc) on themicroinjector to 150–200hPa (1 hPa¼100Pascal).
The injection mix should flow out of the injection capillary
continuously at a relatively slow rate (generally not visible).
With the micromanipulator joystick still set to fine movements,
position the injection capillary directly above the nucleus of an
SCG neuron and lower until it enters the nucleus. If the
injection mix is flowing correctly, the nucleus will swell. Allow
the nucleus to expand by ~10–20% (this should happen rapidly)
and then remove the capillary tip by raising back to its starting
position. Small lateral movements when lowering and raising
the capillary tip will prevent hooking the neuron with the tip. A
graphical representation of the injection procedure is shown in
Fig. 3. Compensation pressure should be adjusted as needed to
optimize the injection process; injection of too much mix at
too fast a rate will kill neurons, whereas injection with too little
will compromise visualization due to low fluorescent marker
expression/concentration. Blockages in the tip that prevent
flow even at high pressures can sometimes be resolved using
the “clean” function on the microinjector (a short blast of high
pressure to the capillary), but the capillary will need to be
replaced if the blockage persists. While the number and loca-
tion of neurons to be injected per dish will depend on the
requirements of the assay being performed, neurite studies
generally benefit from injection of relatively small numbers of
neurons in relatively localized clusters/strips (see Note 11).
7. After injection, move the injection capillary back to its starting
position and reduce the compensation pressure (Pc) on the
microinjector to 0 hPa before removing from the capillary
holder.
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8. Return the cultures to the 5% CO2 incubator at 37
C. It will
take at least 24 h for the distal ends of long neurites of the
injected neurons to become labeled, irrespective of the fluores-
cent injection marker used, but more proximal neurite regions
will be visible immediately with conjugated dextrans and after
just a few hours with an exogenously expressed fluorescent
protein.
9. Optional transection of labeled neurites with a scalpel blade (see
Note 12): After 24–48 h (to allow sufficient labeling of distal
neurites), locate the cluster/strip of injected neurons in the
dish on an inverted fluorescence microscope with the appropri-
ate fluorescence filter and center the cell bodies in the field of
view. Push the transmitted light arm of the microscope back to
give access to the dish on the microscope stage. While viewing
through a protective screen, use the circle of projected incident
light in the dish as a guide to position the point of a curved,
sterile surgical scalpel blade, so that a long, straight cut can be
introduced to one side of the injected neuron cell bodies by
rolling the cutting edge of the scalpel along the surface of the
dish with a single down-and-up movement of the scalpel
holder/handle (see Note 13). Avoid lateral movements of the
blade that might unintentionally cause detachment of the
Fig. 3 Outline of the procedure for microinjecting dissociated SCG neurons. Graphical representations of a
single neuron cell body from the side and from above are shown to illustrate key stages in the injection
procedure. Written guidelines are provided at each stage. The view from above is a stylized view of what the
experimenter will see in the center of the microscope field
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neurite network by bringing the scalpel back to its tip before
removing from the dish. If performed correctly, fluorescently
labeled distal neurites should be completely separated from
their cell bodies (Fig. 1).
10. Monitor/quantify neurite degeneration: Capture images of
intact or transected fluorescently labeled neurites at various
timepoints after initial injection or cutting (or both) on an
inverted fluorescence microscope. Images captured using
10 or 20 objectives should provide sufficient resolution of
individual neurites. What timepoints are used, and whether or
not a cut is performed, will depend on the potential effect of
the injected constructs and/or other reagents being tested.
Healthy, intact neurites will retain a uniform fluorescent signal
along their entire length, whereas the appearance of blebs or
varicosities and/or a loss of continuity of the fluorescent signal
are indicators of degeneration. For example, transected wild-
type SCG neurites begin to show complete loss of continuity of
the fluorescent signal from 6 to 8 h onward (Fig. 1). The
number of intact neurites at any given timepoint can be com-
pared to the number of intact neurites at a reference timepoint
(usually 24 h after injection or just after cut) to calculate
percentage survival/degeneration. The same field of neurites
should be compared at each timepoint (see Note 14).
4 Notes
1. FBS is preferred over B27 supplement for dissociated SCG
cultures and is essential when the neurons are to be microin-
jected. Sources of FBS should first be tested rigorously for their
ability to maintain healthy cultures for at least 7–10 days. Dif-
ferent lots of FBS from the same source can also vary in their
quality. Culture quality can be assessed by observing the mor-
phology of the neuronal somas and neurites; somas should
remain phase bright and have large, round nuclei with visible
nucleoli while neurites should remain relatively smooth and
free from blebs and develop into a dense network of neurite
bundles.
2. Aphidicolin is used as an antimitotic to inhibit proliferation of
non-neuronal cells. A combination of 20 μM fluorodeoxyur-
idine and 20 μM uridine can be used as an alternative to
aphidicolin but is less potent.
3. 7S and 2.5S NGF can be obtained from a number of commer-
cial sources. It is sensible to compare batches from different
sources and to determine empirically the optimal concentration
for healthy cultures.
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4. Low-sided dishes are used, so that as large an area as possible of
the dish is accessible to the angled injection capillary when
microinjecting. The coverslip insert base of ibidi dishes pro-
vides superior optical properties for imaging but is not essen-
tial. Laminin coating defines the area of the dish to which the
neurons can attach and extend their neurites, and this can be
varied, so that similar cell densities can be obtained with differ-
ent numbers of neurons.
5. The methods described in this chapter are specific to the
Eppendorf microinjection system detailed in Subheading 2.2.
Use of other microinjection systems from other manufacturers
may require a different injection technique, but the principles
will be similar. Injections can be performed on a microscope
without a heated stage and/or CO2 supply, but the time cul-
tures are out of the 37 C, 5% CO2 incubator should then be
limited to less than 15 min to avoid significant temperature/
pH stress.
6. Injection capillaries can alternatively be prepared from glass
capillaries using a micropipette puller. A different, specialized
capillary holder will be required for attachment of pulled capil-
laries to the FemtoJet® microinjector.
7. Trituration is the most critical step in the procedure. While
insufficient trituration will result in retention of some neurons
in clumps (not ideal for microinjection but still manageable),
overtrituration can cause substantial loss of neuronal viability
and should be avoided. The two phases of restricted trituration
described in this method minimize the risk of overtrituration.
If necessary, the state of dissociation at each stage can be
monitored by looking at small aliquots of the cell suspension
on an inverted phase-contrast microscope. The final cell sus-
pension should contain mostly individual, phase-bright cells.
Many will still have short neurite stumps attached.
8. The relatively small numbers of non-neuronal cells in disso-
ciated mouse SCG neuron preparations can be managed ade-
quately with antimitotics, such as aphidicolin, without
performing the preplating step. In contrast, preplating is advis-
able if dissociating rat SCG neurons as non-neuronal cells are
generally more abundant.
9. The yield of neurons per ganglion using this method is usually
very reproducible, and the final cell density will generally be
similar between preparations (assuming the same ratio of gang-
lia to plating area is used). However, if variable yield is found to
be a problem, then a determination of cell concentration using
a hemocytometer can ensure that equal numbers of neurons are
plated with each preparation.
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10. The type of fluorescent marker used for visualization of the
injected neurons and their neurites will depend on the poten-
tial outcomes of the assay being performed. Fluorescently con-
jugated dextrans will provide immediate labeling of injected
neuron cell bodies and will rapidly diffuse into proximal neur-
ites, but the signal will weaken as it diffuses along the neurites
and becomes more diluted. In contrast, labeling will be rela-
tively delayed using a fluorescent protein expression vector but
will ultimately be brighter and more prolonged as ever-
increasing levels of the fluorescent protein spread into the
neurites. Conjugated dextrans are thus more suited to situa-
tions where a manipulation induces rapid and early degenera-
tion of otherwise uninjured neurites, while exogenously
expressed fluorescent proteins are generally preferable in all
other cases. However, it is important to consider possible
toxic effects of exogenously expressed fluorescent proteins
resulting from high or prolonged expression [7] and to be
aware that the presence of a fluorescent protein expression
vector can reduce expression from other co-injected constructs
(and vice versa) as a result of competition between promoters
for shared transcription factors. In general, it is best to use the
lowest concentration of fluorescent protein expression vector
that gives adequate visualization of neurites when these issues
arise.
11. The dense neurite network in SCG neuron cultures largely
consists of groups of neurites bundled together in small tracts
rather than individual, isolated neurites. Microinjection of rel-
atively small numbers of neurons thus increases the chances of
visualizing and monitoring survival of individual neurites, even
within a bundle, as opposed to the sum of the health of multi-
ple neurites bundled together. The injection of neurons in
relatively localized clusters or strips has advantages both in
transection and nontransection assays: In transection assays, it
ensures that the whole cluster/strip of injected cell bodies can
easily be restricted to one side of the cut, so that the labeled
neurites on the opposite side of the cut will all be transected
(with a possible caveat—see Note 13), and in non-transection
assays, it facilitates imaging of just the distal portions of the
neurites, mostly in the same orientation, if an area distant to
the cluster/strip of cell bodies is selected.
12. Individual neurites can be transected by laser ablation as an
alternative to transection with a scalpel blade. Chemical insults
can also be used to trigger neuritedegeneration that is mecha-
nistically related to injury-induced (Wallerian) degeneration.
13. It is not necessary for the cut site to extend all the way across
the cultured area of the dish when transecting neurites (indeed
a complete bisection of the culture may increase the chance of
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detachment). However, because neurites in dissociated cul-
tures are branched and sometimes follow a highly convoluted
path, leaving a region of continuity of the neurite network
around the ends of the cut site can result in untransected,
fluorescently labeled neurites being present on the distal side
of the cut. Any neurites being evaluated distal to the cut site
that can be traced around the cut site should thus be excluded
from the analysis.
14. Fluorescently labeled neurites undergoing degeneration initi-
ally develop variable numbers of neuritic swellings along their
length, and this is followed by a loss of continuity. Swellings are
very short lived when degeneration is rapid, for example, after
injury, but can persist for longer before the loss of continuity
following noninjury treatments that induce slower degenera-
tion. Although the remnants of fully degenerated neurites can
remain visible for several hours after degeneration, sometimes
the fluorescent label fades/disintegrates to such an extent that
the degenerated neurite effectively disappears. Calculations of
the percentage of degenerated neurites (with swellings or dis-
continuity of the fluorescent label) in a single field at a single
late timepoint can thus be an unreliable reflection of the actual
extent of degeneration. A more accurate method is to follow
the survival of exactly the same visual field of neurites and
compare the number of healthy intact neurites (with continu-
ous fluorescent labeling and no swellings) at each timepoint
with that of the number present at an early, reference
timepoint.
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